- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RFA vies with surgery for treating liver tumors
Radiofrequency ablation is as effective as resection for treatment of hepatocellular carcinoma, according to a study presented at the joint RSNA/SIR Foundation Interventional Oncology Symposium. The key factor is RFA's ability to easily repeat treatment on recurring tumors in a less destructive fashion than surgery.
Radiofrequency ablation is as effective as resection for treatment of hepatocellular carcinoma, according to a study presented at the joint RSNA/SIR Foundation Interventional Oncology Symposium. The key factor is RFA's ability to easily repeat treatment on recurring tumors in a less destructive fashion than surgery.
Dr. Riccardo Lencioni and colleagues at the University of Pisa compared 38 resections with 124 RFA treatments for patients with single lesions of 5 cm or less. The case-controlled investigation of overall survival rates, tumor progression, and tumor recurrence found a three-year survival rate of 72% for patients treated with RFA versus 65% for those treated with resection. The difference is not statistically significant.
"The long-term survival is the result of a series of treatments," Lencioni said. "A minimally invasive approach is the key because you don't deteriorate the liver function. With surgery, you have the best outcome in terms of local control, but the price is high."
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
